Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, which is a prescription drug approved for use in combination with the company's licensor's medical device; and the RhodoLED lamp series for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. It also Xepi, a prescription cream for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.

Biofrontera Inc.

Biofrontera Inc. is a U.S.-based biopharmaceutical company commercializing a portfolio of dermatological drugs specializing on the fields of photodynamic therapy (PDT) and topical antibiotics. The Company’s licensed products focus on the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. For more information, visit www.biofrontera-us.com.

#NowHiring: The #Biofrontera team is searching for a new Jr. Territory Manager in Chicago, IL! 

If you're ready to make a difference in #dermatology, visit ⤵️

#SalesPosition #ComeGrowWithUs

📢 We're hiring a Territory Manager in Chicago, IL! 

Ready to help the #Biofrontera team spread the word about our innovative dermatological treatments? Apply today ⤵️ 

#ComeGrowWithUs

Today we shared #Bioftonera's #Q3 financial results for 2023. To learn more, visit the link below: ⤵️

#BiofronteraNews #Dermatology

Meet #Biofrontera Quality Assurance Director, Darrell Lowman! Darrell has been instrumental in our success as a company and is a natural-born leader. We are lucky to have him!

To learn more about our team, visit: https://loom.ly/xeWeBoE

#GetToKnowUs #PDT #EmployeeSpotlight #Dermatology

Are you a #Dermatology NP or PA and looking to transition to industry? Are you located in the Northeast? Do you want to join a dynamic team and fuel your career growth? If so, please check out #Biofrontera's open position for a Medical Science Liaison. ⤵️

#ComeGrowWithUs #NowHiring

#Biofrontera was happy to support and take part in the YoungMD Connect Networking Event this weekend in Chicago, connecting with some of the rising stars of #dermatology!

Thank you to Sally Cioci Fischer and the Practical Dermatology team for organizing such a great event!

Mouna Mikati, Ph.D. Kristina Malkhasova, Pharm. D. 

#BiofronteraontheMove

Join the #Biofrontera team as a Senior Financial Analyst at our headquarters in Woburn, MA! 

Discover how you can help to make a difference in #dermatology. Apply now ⤵️

We had a great time at the Ohio Dermatological Annual Meeting this past weekend! It's always a pleasure running into Dr. Scott Drew and Delaney Drew.

Thank you to our own Amy Ward Cline for holding down the booth and sharing the latest about 

#Biofrontera! #BiofronteraOnTheMove #Dermatology

We have news! To learn more about the latest #Biofrontera updates, visit: https://loom.ly/ZfcmM4o

#BiofronteraNews #Dermatology

Happy Halloween from all of us at #Biofrontera! Our latest training class joined some of our HQ team for a spooktacular time at our annual Halloween celebration. 

We celebrated with a costume contest as well a painting contest and DIY cookie decorating!

	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
revenue	26.18M -	18.85M 28.01%	24.10M 27.86%	28.67M 18.98%	34.07M 18.82%
cost of revenue	12.41M -	9.07M 26.93%	12.74M 40.55%	15.19M 19.17%	18.51M 21.88%
gross profit	13.77M -	9.78M 28.97%	11.36M 16.10%	13.49M 18.76%	15.56M 15.38%
selling and marketing expenses					-2.29M -
general and administrative expenses	28.70M -	18.12M 36.86%	37.21M 105.38%	35.87M 3.60%	39.13M 9.08%
selling general and administrative expenses	28.70M -	18.12M 36.86%	37.21M 105.38%	35.87M 3.60%	36.84M 2.70%
research and development expenses					77K -
other expenses	5.48M -	1.25M 77.12%	689K 45.01%	33K 95.21%	131K 296.97%
cost and expenses	41.10M -	27.18M 33.87%	49.95M 83.76%	51.05M 2.21%	55.42M 8.56%
operating expenses	28.70M -	18.12M 36.86%	37.21M 105.38%	35.87M 3.60%	36.91M 2.91%
interest expense	2.16M -	2.90M 34.18%	344K 88.13%	195K 43.31%	600K 207.69%
ebitda	-8.75M -	-6.49M 25.85%	-25.16M 287.64%	-21.18M 15.84%	-20.29M 4.19%
operating income	-14.92M -	-8.33M 44.15%	-25.85M 210.19%	-22.38M 13.42%	-21.35M 4.60%
depreciation and amortization	6.17M -	1.84M 70.12%	689K 62.62%	1.21M 74.89%	1.06M 11.70%
total other income expenses net	3.97M -	-2.59M 165.16%	-11.81M 356.01%	21.77M 284.42%	1.24M 94.33%
income before tax	-10.95M -	-10.92M 0.24%	-37.66M 244.75%	-608K 98.39%	-20.12M 3,208.72%
income tax expense	33K -	64K 93.94%	56K 12.50%	32K 42.86%	14K 56.25%
net income	-10.98M -	-10.99M 0.05%	-37.71M 243.25%	-640K 98.30%	-20.13M 3,045.47%
weighted average shs out	580K -	580K 0%	440.41K 24.07%	21.14M 4,700.01%	1.55M 92.69%
weighted average shs out dil	580K -	580K 0%	440.41K 24.07%	21.14M 4,700.01%	1.55M 92.69%
eps	-18.93 -	-18.94 0.05%	-85.63 352.11%	-0.03 99.96%	-13.02 42,870.30%
epsdiluted	-18.93 -	-18.94 0.05%	-85.63 352.11%	-0.03 99.96%	-13.02 42,870.30%

COM:BIOFRONTERA-US

Biofrontera Inc.

Last Close

0.76

22/11 21:00

Market Cap

4.99M

Beta: -

Volume Today

820.43K

Avg: -

Preview